David Spigel, MD

Name: Tumor Board: Advances in Managing EGFR-Mutant NSCLC: Applying Evidence Across the Disease Continuum
Start: 2025-09-07T18:30:00+02:00
End: 2025-09-07T19:30:00+02:00

September 1, 2016

|

By

|

Estimated Read Time:

1 minute

Names & News

David Spigel has been appointed chief scientific officer of Sarah Cannon Research Institute, Nashville, US, and will oversee the development and operations of Sarah Cannon’s clinical research program. Dr. Spigel joined Sarah Cannon in 2003 as the director of the lung cancer research program.

About the Authors

Share this Article:

David Spigel, MD

Recent Posts

Meet Us in Barcelona: What to Expect at the World Conference on Lung Cancer

Celebrate the IASLC Foundation’s Impact

Step it Up at WCLC 2025 in Barcelona

Know Before You Go: Your Guide to Navigating Barcelona

IS03: Satellite EBAC/CME Symposium by Answers in CME: Reshaping the Management of Metastatic NSCLC: Tackling HER2 Overexpression to Elevate Outcomes

Tumor Board: Advances in Managing EGFR-Mutant NSCLC: Applying Evidence Across the Disease Continuum

COCOON’s Prophylactic Regimen Resulted in Decreased Incidence and Severity of Dermatologic-related Adverse Events

MARIPOSA OS Data Confirms Improved Efficacy for Amivantamab Plus Lazertinib in the First Line for EGFR-mutated NSCLC